OutSee has raised $2.0M in total across 1 funding round.
OutSee's investors include Elbow Beach Capital.
OutSee is a Cambridge-based genomics and drug discovery startup developing Nomaly, an AI-powered predictive genomics engine that predicts disease and phenotype directly from a single genome using fundamental molecular and cellular biology, rather than pattern-matching known genetic associations.[1][2][3][6] It serves pharmaceutical and biotech companies by uncovering novel drug targets, validating mechanisms, and enabling patient stratification from existing or small genomic datasets, addressing underexploited data in areas like CNS, rare, and metabolic diseases.[2][3][5][6] The company has secured £1.8M ($2.4M) in seed funding in June 2025 from Ahren Innovation Capital, Kadmos Capital, Empirical Ventures, and Panacea Ventures, plus over £500k in Innovate UK grants, fueling in-house programs and pharma partnerships amid strong early momentum.[3][5]
OutSee was founded by Dr. Julian Gough, CEO, a serial entrepreneur and Cambridge Enterprise Academic Entrepreneur of the Year 2020, who envisioned the core approach a decade ago in academia, and Chang Lu, both with roots at the MRC Laboratory of Molecular Biology (LMB).[2][4] Gough, who served as PhD student, postdoc, and group leader in Structural Studies at LMB (1998-2002, 2017-2023), recognized the untapped potential in large-scale genomics datasets despite advances in sequencing.[2][4] The idea evolved from academic concepts to a startup on Cambridge University grounds, shifting from traditional "Does the data contain my answer?" queries to a "genetics-first" predictive model based on biology knowledge, with early validation via Innovate UK grants for dementia studies.[2][3][5]
OutSee rides the AI-genomics wave post-human genome project, where sequencing surged but analysis lagged, now amplified by pharma's push into precision medicine amid vast, underused datasets.[2][6] Timing aligns with 2025's funding surge for AI-drug discovery, as noted by experts like Nobel winner David Baker on targeting challenges beyond protein binding.[6] Market forces favor it: biotech's need for novel targets in complex diseases (e.g., dementia, rare conditions), smaller datasets' viability, and re-mining old data reduce costs/barriers.[3][5][6] It influences the ecosystem by complementing pipelines, accelerating target ID/validation, and enabling "genomics-first" strategies that pharma adopts for faster, data-efficient R&D.[2][3]
OutSee's seed funding positions it to scale Nomaly via internal pipelines and pharma deals, potentially yielding first therapeutic hypotheses in 1-2 years.[2][3] Trends like AI's leap in multi-omics integration and rare disease focus will propel it, evolving its role from tool provider to ecosystem shaper in predictive drug discovery. As genomics data explodes, OutSee could redefine target hunting, turning single-genome insights into precision medicine breakthroughs—bridging the gap from raw biology to novel therapies.[6]
OutSee has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $2.0M Seed | Elbow Beach Capital |
